Warwick Clinical Trials Unit:
Cancer Research
www.warwick.ac.uk/go/ctu
Experience
Overview
Future Aims
The cancer team at Warwick CTU was established in January 2006
under the leadership of Professor Janet Dunn. It provides support and
expertise in the design, conduct, analyses and reporting of national,
multicentre, cancer clinical trials. The team has an excellent track
record of conducting trials in early breast, GI, colorectal, melanoma
and multiple myeloma with an impressive publication record in high
impact journals e.g. NEJM, JCO, Blood, Lancet, BMJ.
Warwick Clinical Trials Unit is an academic unit undertaking clinical
trials addressing real issues of local, national and international
importance. It gained UKCRC full CTU registration status in 2007
which demonstrates the quality and national reputation of the CTU.
Establish Warwick as a National Cancer Research Institute (NCRI)
accredited cancer clinical trials unit and continue to deliver high impact
clinical trials within the national portfolio of cancer trials.
Expand the Warwick programme of head and neck cancer research.
The Warwick CTU cancer team are conducting national trials in early
breast, ovarian and head and neck cancers, as well as providing the
randomisation, programming and statistical support for national trials
of melanoma, stomach cancer and myeloma.
The team specialises in the application of complex statistical methods
needed for large scale cancer trials e.g. survival analysis, evaluation of
prognostic and predictive indices, handling of missing data and
analysis of potential biomarkers.
Continue to work closely with the Arden Cancer Network under the
leadership of Professor Bob Grieve, providing support to local Chief
Investigators.
Establish the early phase clinical trials unit at UHCW under the
leadership of Professor Chris Poole.
Total grant income of £6 million has been awarded to the Warwick
CTU cancer trials over the last 3 years, supporting the following trials:
Persephone
PET-Neck
NEO-ESCAPE
ARTemis
A phase III rial comparing 6 months Trastuzamab
treatment with 12 months in women with early stage
breast cancer
A phase III trial comparing PET-CT guided watch and
wait policy versus planned neck dissection for the
management of advanced (N2/N3) nodal metastases in
patients with head and neck squamous cancer
A phase II feasibility trial of neoadjuvant sequential
chemotherapy with adjuvant post operative treatment for
epithelial non-mucinous advanced inoperable peritoneal
malignancy
A phase III Avastin Randomised Trial with neo-adjuvant
chemotherapy for patients with early breast cancer
Chief Investigator: Dr Helena Earl, Addenbroke’s Hospital
Chief Investigator: Mr Hisham Mehanna, UHCW
Chief Investigator: Dr Chris Poole, UHCW
Chief Investigator: Dr Helena Earl, Adenbrookes Hospital
Primary Objective: Disease free survival non-inferiority
(equivalence) of 6 months vs 12 months Trastuzamab.
Primary Objective: Non-inferiority of PET-CT surveillance
compared with planned neck dissection.
Primary Objective:
chemotherapy.
Recruitment target:
Recruitment to date:
Recruitment target:
Recruitment to date:
Recruitment target:
Recruitment to date:
4,000 patients
133 patients
Contact
Jas Sandhu
j.sandhu@warwick.ac.uk
(024) 761 50492
POSTER TEMPL ATE BY:
www.PosterPresentations.com
560 patients
32 patients
Contact
Claire Balmer
c.balmer@warwick.ac.uk
(024) 761 50478
Completion
of
Contact
Primary Objective: Complete pathological response rates
(no residual invasive carcinoma and no evidence of
metastatic disease within lymph nodes)
Recruitment target:
800 patients
Recruitment to date:
to start April 2009
Contact
Julie Fletcher
j.fletcher@warwick.ac.uk
(024) 769 68620
Claire Daffern
artemis@warwick.ac.uk
(024) 761 50605
88 patients
13 patients
12
cycles
of